MannKind (MNKD) Q2 Revenue Rises 6%

MannKind (NASDAQ:MNKD), a biopharmaceutical firm known for its inhaled insulin and pulmonary therapeutics, released its second quarter 2025 earnings on August 6, 2025. The most significant news from this release was a 6% increase in total revenue to $76.53 million (GAAP), primarily from royalty gains and higher Afrezza inhaled insulin sales. However, this figure was nearly $2.3 million below the $78.8 million analyst consensus. Non-GAAP earnings per share remained flat year over year at $0.05, aligned exactly with expectations. Progress in key pipeline programs and substantial increases in operating expenses raised execution questions as the company pursues growth. Source: Analyst estimates for the quarter provided by FactSet. MannKind (NASDAQ:MNKD) develops and manufactures inhalable therapies, mainly targeting diabetes and rare lung diseases. Its flagship product is Afrezza, an inhaled insulin powder designed to offer rapid-acting blood sugar control for people with diabetes. MannKind's business also includes V-Go, a wearable insulin delivery device, and partnership-derived revenues from production and royalties on Tyvaso DPI, an inhaled treatment for pulmonary hypertension developed by United Therapeutics.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool